An Observational Cohort Study of the Use of Avatrombopag in Patients With Thrombocytopenia Associated With Chronic Liver Disease Undergoing a Procedure
Phase of Trial: Phase IV
Latest Information Update: 11 Mar 2019
Price : $35 *
At a glance
- Drugs Avatrombopag (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- Sponsors Dova Pharmaceuticals
- 06 Mar 2019 Status changed from recruiting to discontinued.
- 22 Jun 2018 Status changed from not yet recruiting to recruiting.
- 20 Jun 2018 New trial record